炎性细胞与动脉性肺动脉高压血管重塑

doi:10.16352/j.issn.1001-6325.2024.08.1080

摘要/Abstract

摘要： 动脉性肺动脉高压(pulmonary arterial hypertension, PAH)是一类严重的渐进性肺血管疾病,主要特征为肺小动脉病变引起的肺血管阻力持续性增加以及肺动脉压进行性升高,进而导致右心衰竭甚至死亡。肺血管重塑是PAH的特征性病理改变,其发生机制涉及基因易感性、血管活性分子失衡、离子通道及信号通路异常等多种因素;近年研究发现,炎性反应在肺血管重塑机制中起着关键作用。在PAH患者和动物模型的肺血管周围发现有大量炎性细胞浸润;此外,在外周血中还检测到显著升高的细胞因子及自身抗体等,并且这些与PAH的不良预后密切相关。本文将对炎性细胞在PAH血管重塑发生中作用的研究进展进行综述,为开发安全有效的PAH治疗方法提供新思路。

关键词: 动脉性肺动脉高压, 肺血管重塑, 炎性反应, 炎性细胞

Abstract: Pulmonary arterial hypertension (PAH) is a severe and progressive pulmonary vascular disease mainly characterized by a continuous increase in pulmonary vascular resistance and rise of pulmonary artery pressure caused by pulmonary arteriolar lesions, ultimately resulting in right heart failure and even death. Pulmonary vascular remodeling is a characteristic pathological change of PAH, and its mechanism involves gene susceptibility, imbalance of vasoactive substances, abnormal energy metabolism and other potential factors. Recent studies have found that inflammatory reaction plays a crucial role in the mechanism of pulmonary vascular remodeling. Inflammatory cells are found to infiltrate and accumulate around the pulmonary vessels of PAH patients and of animal models. In addition, significantly high level of cytokines and auto-antibodies were also found in peripheral blood, which is closely related to poor prognosis of PAH. This article reviews the research progress about the potential role of inflammatory cells in the vascular remodeling of PAH and provides new ideas for developing of safe and effective treatment methods for PAH.

Key words: pulmonary arterial hypertension, pulmonary vascular remodeling, inflammation, inflammatory cells

中图分类号:

R543.2

钱喜锋, 华潞. 炎性细胞与动脉性肺动脉高压血管重塑[J]. 基础医学与临床, 2024, 44(8): 1080-1087.

QIAN Xifeng, HUA Lu. Inflammatory cells and vascular remodeling in pulmonary arterial hypertension[J]. Basic & Clinical Medicine, 2024, 44(8): 1080-1087.

参考文献

[1] 中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101:11-51.
[2] Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review[J]. Pulm Circ, 2021, 11:2045894020977300. doi:10.1177/2045894020977300.
[3] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志, 2023, 38:583-612.
[4] Huertas A, Tu L, Humbert M, et al. Chronic inflamma-tion within the vascular wall in pulmonary arterial hypertension: more than a spectator[J]. Cardiovasc Res, 2020, 116:885-893.
[5] Hu Y, Chi L, Kuebler WM, et al. Perivascular inflammation in pulmonary arterial hypertension[J]. Cells, 2020, 9:2338. doi:10.3390/cells9112338.
[6] Wang RR, Yuan TY, Wang JM, et al. Immunity and inflammation in pulmonary arterial hypertension: from pathophysiology mechanisms to treatment perspective[J]. Pharmacol Res, 2022, 180:106238. doi:10.1016/j.phrs.2022.106238.
[7] Maston LD, Jones DT, Giermakowska W, et al. Central role of T helper 17 cells in chronic hypoxia-induced pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2017, 312:L609-L624.
[8] Chen G, Zuo S, Tang J, et al. Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice[J]. J Exp Med, 2018, 215:2175-2195.
[9] Xiao Q, Li X, Li Y, et al. Biological drug and drug delivery-mediated immunotherapy[J]. Acta Pharm Sin B, 2021, 11:941-960.
[10] Tian W, Jiang SY, Jiang X, et al. The role of regulatory T cells in pulmonary arterial hypertension[J]. Front Immunol, 2021, 12:684657. doi:10.3389/fimmu.2021.684657.
[11] Esensten JH, Muller YD, Bluestone JA, et al. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier[J]. J Allergy Clin Immunol, 2018, 142:1710-1718.
[12] Ferreira LMR, Muller YD, Bluestone JA, et al. Next-generation regulatory T cell therapy[J]. Nat Rev Drug Discov, 2019, 18:749-769.
[13] Tamura Y, Phan C, Tu L, et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension[J]. J Clin Invest, 2018, 128:1956-1970.
[14] Toshner M, Church C, Harbaum L, et al. Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension[J]. Eur Respir J, 2022, 59:2002463. doi:10.1183/13993003.02463-2020.
[15] Yang PS, Kim DH, Lee YJ, et al. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats[J]. Respir Res, 2014, 17:142. doi:10.1186/s12931-014-0148-4.
[16] Parpaleix A, Amsellem V, Houssaini A, et al. Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension[J]. Eur Respir J, 2016, 48:470-483.
[17] Trankle CR, Canada JM, Kadariya D, et al. IL-1 blockade reduces inflammation in pulmonary arterial hypertension and right ventricular failure: a single-arm, open-label, phase IB/Ⅱ pilot study[J]. Am J Respir Crit Care Med, 2019, 199:381-384.
[18] Shu T, Xing Y, Wang J. Autoimmunity in pulmonary arterial hypertension: evidence for local immunoglobulin production[J]. Front Cardiovasc Med, 2021, 8:680109. doi:10.3389/fcvm.2021.680109.
[19] Marsh LM, Jandl K, Grünig G, et al. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension[J]. Eur Respir J, 2018, 51:1701214. doi:10.1183/13993003.01214-2017.
[20] Breitling S, Hui Z, Zabini D, et al. The mast cell-B cell axis in lung vascular remodeling and pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2017, 312:L710-L721.
[21] Colvin KL, Cripe PJ, Ivy DD, et al. Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies[J]. Am J Respir Crit Care Med, 2013, 188:1126-1136.
[22] Wang J, Qian J, Wang Y, et al. Serological biomarkers as risk factors of SLE-associated pulmonary arterial hypertension: a systematic review and meta-analysis[J]. Lupus, 2017, 26:1390-1400.
[23] Zamanian RT, Badesch D, Chung L, et al. Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial[J]. Am J Respir Crit Care Med, 2021, 204:209-221.
[24] Hennigan S, Channick RN, Silverman GJ. Rituximab treatment of pulmonary arterial hypertension associated with systemic lupus erythematosus: a case report[J]. Lupus, 2008, 17:754-756.
[25] Deng L, Jian Z, Xu T, et al. Macrophagepolarization: an important candidate regulator for lung diseases[J]. Molecules, 2023, 28:2379. doi:10.3390/molecules28052379.
[26] Fan Y, Hao Y, Gao D, et al. Phenotype and function of macrophage polarization in monocrotaline-induced pulmonary arterial hypertension rat model[J]. Physiol Res, 2021, 70:213-226.
[27] Abid S, Marcos E, Parpaleix A, et al. CCR2/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension[J]. Eur Respir J, 2019, 54:1802308. doi:10.1183/13993003.02308-2018.
[28] Pullamsetti SS, Savai R. Macrophage regulation during vascular remodeling: implications for pulmonary hypertension therapy[J]. Am J Respir Cell Mol Biol, 2017, 56:556-558.
[29] Mamazhakypov A, Viswanathan G, Lawrie A, et al. The role of chemokines and chemokine receptors in pulmonary arterial hypertension[J]. Br J Pharmacol, 2021, 178:72-89.
[30] Tian W, Jiang X, Tamosiuniene R, et al. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension[J]. Sci Transl Med, 2013, 5:200ra117. doi:10.1126/scitranslmed.3006674.
[31] Qian J, Tian W, Jiang X, et al. Leukotriene B4 activates pulmonary artery adventitial fibroblasts in pulmonary hypertension[J]. Hypertension, 2015, 66:1227-1239.
[32] Tian W, Jiang X, Sung YK, et al. Leukotrienes in pulmonary arterial hypertension[J]. Immunol Res, 2014, 58:387-393.
[33] Mercurio V, Cuomo A, Naranjo M, et al. Inflammatory mechanisms in the pathogenesis of pulmonary arterial hypertension: recent advances[J]. Compr Physiol, 2021, 11:1805-1829.
[34] Tian W, Jiang X, Sung YK, et al. Phenotypically silent bone morphogenetic protein receptor 2 mutations predispose rats to inflammation-induced pulmonary arterial hypertension by enhancing the risk for neointimal transformation[J]. Circulation, 2019, 140:1409-1425.
[35] Kosanovic D, Dahal BK, Peters DM, et al. Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease[J]. Pulm Circ, 2014, 4:128-136.
[36] Kwapiszewska G, Markart P, Dahal BK, et al. PAR-2 inhibition reverses experimental pulmonary hypertension[J]. Circ Res, 2012, 110:1179-1191.
[37] Sismanopoulos N, Delivanis DA, Alysandratos KD, et al. IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis[J]. PLoS One, 2012, 7:e33271. doi:10.1371/journal.pone.0033271.
[38] Farha S, Sharp J, Asosingh K, et al. Mast cell number, phenotype, and function in human pulmonary arterial hypertension[J]. Pulm Circ, 2012, 2:220-228.
[39] Carroll-Portillo A, Cannon JL, te Riet J, et al. Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation[J]. J Cell Biol, 2015, 210:851-864.
[40] Bulfone-Paus S, Bahri R. Mast cells as regulators of T cell responses[J]. Front Immunol, 2015, 6:394. doi:10.3389/fimmu.2015.00394.
[41] Hu Y, Zabini D, Gu W, et al. The role of the human immune system in chronic hypoxic pulmonary hypertension[J]. Am J Respir Crit Care Med, 2018, 198:528-531.
[42] Dahal BK, Kosanovic D, Kaulen C, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats[J]. Respir Res, 2011, 12:60. doi:10.1186/1465-9921-12-60.
[43] Perros F, Dorfmüller P, Souza R, et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension[J]. Eur Respir J, 2007, 29:462-468.
[44] Larsen KO, Yndestad A, Sjaastad I, et al. Lack of CCR7 induces pulmonary hypertension involving perivascular leukocyte infiltration and inflammation[J]. Am J Physiol Lung Cell Mol Physiol, 2011, 301:L50-L59.
[45] Fleige H, Bosnjak B, Permanyer M, et al. Manifold roles of CCR7 and its ligands in the induction and maintenance of bronchus-associated lymphoid tissue[J]. Cell Rep, 2018, 23:783-795.
[46] Van Uden D, Boomars K, Kool M. Dendritic cell subsets and effector function in idiopathic and connective tissue disease-associated pulmonary arterial hypertension[J]. Front Immunol, 2019, 10:11. doi:10.3389/fimmu.2019.00011.
[47] Funk-Hilsdorf TC, Behrens F, Grune J, et al. Dysregu-lated immunity in pulmonary hypertension: from compa-nion to composer[J]. Front Physiol, 2022, 13:819145. doi:10.3389/fphys.2022.819145.
[48] Liu X, Mayes MD, Tan FK, et al. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis[J]. Arthritis Rheum, 2013, 65:226-235.
[49] Yang T, Li ZN, Chen G, et al. Increased levels of plasma CXC-chemokine ligand 10, 12 and 16 are associated with right ventricular function in patients with idiopathic pulmonary arterial hypertension[J]. Heart Lung, 2014, 43:322-327.
[50] Rose F, Hattar K, Gakisch S, et al. Increased neutrophil mediator release in patients with pulmonary hypertension--suppression by inhaled iloprost[J]. Thromb Haemost, 2003, 90:1141-1149.
[51] Zaidi SH, You XM, Ciura S, et al. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension[J]. Circulation, 2002, 105:516-521.
[52] Porto BN, Stein RT. Neutrophil extracellular traps in pulmonary diseases: too much of a good thing?[J]. Front Immunol, 2016, 7:311. doi:10.3389/fimmu.2016.00311.
[53] Aldabbous L, Abdul-Salam V, McKinnon T, et al. Neutrophil extracellular traps promote angiogenesis: evidence from vascular pathology in pulmonary hypertension[J]. Arterioscler Thromb Vasc Biol, 2016, 36:2078-2087.
[54] Edwards AL, Gunningham SP, Clare GC, et al. Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension[J]. Respirology, 2013, 18:1271-1277.
[55] Ormiston ML, Deng Y, Stewart DJ, et al. Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension[J]. Am J Respir Cell Mol Biol, 2010, 43:546-554.
[56] Ormiston ML, Chang C, Long LL, et al. Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension[J]. Circulation, 2012, 126:1099-1109.